Pharminent

Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase 2 trial

COPENHAGEN (Reuters) – Danish drugmaker Novo Nordisk said on Friday a phase 2 trial for its big hope in tackling obesity, an improved GLP-1 drug called semaglutide, showed a weight loss of up to 13.8 percent in people with severe conditions.

http://www.reuters.com/article/us-novo-nordisk-obesity-semaglutide-idUSKBN19E29X

Filed under: Metabolic

Eisai and Arena Pharmaceuticals Announce Regulatory Approval of BELVIQ® (lorcaserin HCl) in Brazil

WOODCLIFF LAKE, N.J. and SAN DIEGO, Dec. 19, 2016 /PRNewswire/ — Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Eisai Laboratórios Ltda., a subsidiary of Eisai Inc., has received regulatory approval from the Brazilian Health Surveillance Agency (ANVISA)… http://www.prnewswire.com/news-releases/eisai-and-arena-pharmaceuticals-announce-regulatory-approval-of-belviq-lorcaserin-hcl-in-brazil-300381261.html

Filed under: Metabolic

Eisai, Arena release BELVIQ XR weight-loss drug

http://americanpharmacynews.com/stories/511015178-eisai-arena-release-belviq-xr-weight-loss-drug

Filed under: Metabolic

Valeant Acquires Canadian Rights to Orexigen’s Obesity Treatment

NewsValeant Canada and its affiliates entered a commercialization and distribution agreement with Orexigen Therapeutics for Contrave.Topics: Pharma Mergers & Acquistions http://www.dddmag.com/news/2016/08/valeant-acquires-canadian-rights-orexigens-obesity-treatment

Filed under: Metabolic

Slow Medicine: Empagliflozin Heart Benefits? Not So Fast

(MedPage Today) — EMPA-REG study has several caveats http://www.medpagetoday.com/Cardiology/Diabetes/55536

Filed under: Diabetes, Metabolic

Categories